Kida Yujiro, Goligorsky Michael S
Departments of Medicine, Pharmacology, and Physiology, Renal Research Institute, New York Medical College, Valhalla, New York, USA.
Departments of Medicine, Pharmacology, and Physiology, Renal Research Institute, New York Medical College, Valhalla, New York, USA.
Can J Cardiol. 2016 May;32(5):634-41. doi: 10.1016/j.cjca.2015.11.022. Epub 2015 Dec 8.
The sirtuins (SIRTs) constitute a class of proteins with nicotinamide adenine dinucleotide-dependent deacetylase or adenosine diphosphate-ribosyltransferase activity. Seven SIRT family members have been identified in mammals, from SIRT1, the best studied for its role in vascular aging, to SIRT7. SIRT1 and SIRT2 are localized in the nucleus and cytoplasm. SIRT3, SIRT4, and SIRT5 are mitochondrial, and SIRT6 and SIRT7 are nuclear. Extensive studies have clearly revealed that SIRT proteins regulate diverse cell functions and responses to stressors. Vascular aging involves the aging process (senescence) of endothelial and vascular smooth muscle cells. Two types of cell senescence have been identified: (1) replicative senescence with telomere attrition; and (2) stress-induced premature senescence without telomere involvement. Both types of senescence induce vascular cell growth arrest and loss of vascular homeostasis, and contribute to the initiation and progression of cardiovascular diseases. Previous mechanistic studies have revealed in detail that SIRT1, SIRT3, and SIRT6 show protective functions against vascular aging, and definite vascular function of other SIRTs is under investigation. Thus, direct SIRT modulation and nicotinamide adenine dinucleotide stimulation of SIRT are promising candidates for cardiovascular disease therapy. A small number of pilot studies have been conducted to assess SIRT modulation in humans. These clinical studies have not yet provided convincing evidence that SIRT proteins alleviate morbidity and mortality in patients with cardiovascular diseases. The outcomes of multiple ongoing clinical trials are awaited to define the efficacy of SIRT modulators and SIRT activators in cardiovascular diseases, along with the potential adverse effects of chronic SIRT modulation.
沉默调节蛋白(SIRTs)是一类具有烟酰胺腺嘌呤二核苷酸依赖性脱乙酰酶或二磷酸腺苷核糖基转移酶活性的蛋白质。在哺乳动物中已鉴定出7个SIRT家族成员,从在血管衰老中作用研究最多的SIRT1到SIRT7。SIRT1和SIRT2定位于细胞核和细胞质。SIRT3、SIRT4和SIRT5定位于线粒体,而SIRT6和SIRT7定位于细胞核。广泛的研究清楚地表明,SIRT蛋白调节多种细胞功能和对应激源的反应。血管衰老涉及内皮细胞和血管平滑肌细胞的衰老过程(老化)。已鉴定出两种细胞衰老类型:(1)伴有端粒磨损的复制性衰老;(2)不涉及端粒的应激诱导的早衰。这两种衰老类型均诱导血管细胞生长停滞和血管稳态丧失,并促进心血管疾病的发生和发展。先前的机制研究已详细揭示,SIRT1、SIRT3和SIRT6对血管衰老具有保护作用,其他SIRTs的明确血管功能正在研究中。因此,直接调节SIRT和用烟酰胺腺嘌呤二核苷酸刺激SIRT有望成为心血管疾病治疗的候选方法。已进行了少量的初步研究来评估人类中的SIRT调节。这些临床研究尚未提供令人信服的证据表明SIRT蛋白可减轻心血管疾病患者的发病率和死亡率。正在进行的多项临床试验的结果有待确定SIRT调节剂和SIRT激活剂在心血管疾病中的疗效,以及长期调节SIRT的潜在不良反应。